Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Fredrik Lehmann"'
Autor:
Juho Miettinen, Philipp Sergeev, Sadiksha Adhikari, Maiju-Emilia Huppunen, Minna Suvela, Ana Slipicevic, Nina N Nupponen, Klara Acs, Fredrik Lehmann, Caroline Heckman
Publikováno v:
HemaSphere, Vol 7, p e9358540 (2023)
Externí odkaz:
https://doaj.org/article/b5e07e40eb0946358c2f67ca8dcfbc15
Autor:
Ken Flanagan, Romika Kumari, Juho J. Miettinen, Staci L. Haney, Michelle L. Varney, Jacob T. Williams, Muntasir M. Majumder, Minna Suvela, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Sarah A. Holstein, Caroline A. Heckman
Publikováno v:
HemaSphere, Vol 6, Iss 3, p e687 (2022)
Immunoglobulin light-chain (AL) amyloidosis is a rare disease caused by clonal plasma cell secretion of misfolded light chains that assemble as toxic amyloid fibrils, depositing in vital organs including the heart and kidneys, causing organ dysfuncti
Externí odkaz:
https://doaj.org/article/9b8d9fd8a74e40a7942a0ec1bf52d4d7
Autor:
Alexander Schepsky, Gunnhildur Asta Traustadottir, Jon Petur Joelsson, Sævar Ingthorsson, Jennifer Kricker, Jon Thor Bergthorsson, Arni Asbjarnarson, Thorkell Gudjonsson, Nina Nupponen, Ana Slipicevic, Fredrik Lehmann, Thorarinn Gudjonsson
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6726-6738 (2020)
Abstract Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide‐conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells
Externí odkaz:
https://doaj.org/article/5b8204561d5640db964aa4eb74a5b510
Autor:
Jon Petur Joelsson, Jennifer A. Kricker, Ari J. Arason, Snaevar Sigurdsson, Bryndis Valdimarsdottir, Fridrik Runar Gardarsson, Clive P. Page, Fredrik Lehmann, Thorarinn Gudjonsson, Saevar Ingthorsson
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background The airway epithelium (AE) forms the first line of defence against harmful particles and pathogens. Barrier failure of the airway epithelium contributes to exacerbations of a range of lung diseases that are commonly treated with A
Externí odkaz:
https://doaj.org/article/68af876a3a5d4feaab0da207655852e8
Autor:
Konstantin Byrgazov, Thomas Lind, Annica J. Rasmusson, Claes Andersson, Ana Slipicevic, Fredrik Lehmann, Joachim Gullbo, Håkan Melhus, Rolf Larsson, Mårten Fryknäs
Publikováno v:
Bone Reports, Vol 15, Iss , Pp 101098- (2021)
Myeloma bone disease is a major complication in multiple myeloma affecting quality of life and survival. It is characterized by increased activity of osteoclasts, bone resorbing cells. Myeloma microenvironment promotes excessive osteoclastogenesis, a
Externí odkaz:
https://doaj.org/article/cd014e14ebe249af86995086ee1a9c0e
Autor:
Konstantin Byrgazov, Andrej Besse, Marianne Kraus, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, Lenka Besse
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e602 (2021)
Introduction of the proteasome inhibitor bortezomib has dramatically improved clinical outcomes in multiple myeloma. However, most patients become refractory to bortezomib-based therapies. On the molecular level, development of resistance to bortezom
Externí odkaz:
https://doaj.org/article/5b74bd320c2440168f319eecd0ee0e6a
Autor:
Ari Jon Arason, Jon Petur Joelsson, Bryndis Valdimarsdottir, Snaevar Sigurdsson, Alexander Gudjonsson, Skarphedinn Halldorsson, Freyr Johannsson, Ottar Rolfsson, Fredrik Lehmann, Saevar Ingthorsson, Paulina Cherek, Gudmundur H. Gudmundsson, Fridrik R. Gardarsson, Clive P. Page, Olafur Baldursson, Thorarinn Gudjonsson, Jennifer A. Kricker
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-19 (2019)
Abstract Background Azithromycin (Azm) is a macrolide recognized for its disease-modifying effects and reduction in exacerbation of chronic airway diseases. It is not clear whether the beneficial effects of Azm are due to its anti-microbial activity
Externí odkaz:
https://doaj.org/article/c8da4be92fa246189c8660fe3fd024d1
Autor:
Arjen Gebraad, Roope Ohlsbom, Juho J. Miettinen, Promise Emeh, Toni-Karri Pakarinen, Mikko Manninen, Antti Eskelinen, Kirsi Kuismanen, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Caroline A. Heckman, Susanna Miettinen
Publikováno v:
Cells, Vol 11, Iss 9, p 1574 (2022)
Mesenchymal stem/stromal cells (MSCs) are self-renewing and multipotent progenitors, which constitute the main cellular compartment of the bone marrow stroma. Because MSCs have an important role in the pathogenesis of multiple myeloma, it is essentia
Externí odkaz:
https://doaj.org/article/d9cff7016b3741deb6937edcdb9319eb
Autor:
Konstantin Byrgazov, Claes Anderson, Benjamin Salzer, Eva Bozsaky, Rolf Larsson, Joachim Gullbo, Manfred Lehner, Fredrik Lehmann, Ana Slipicevic, Leo Kager, Mårten Fryknäs, Sabine Taschner-Mandl
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Low survival rates in metastatic high-grade osteosarcoma (HGOS) have remained stagnant for the last three decades. This study aims to investigate the role of aminopeptidase N (ANPEP) in HGOS progression and its targeting with a novel lipo
Externí odkaz:
https://doaj.org/article/17f19891afa74cb9b7cb91bdd80f702b
Publikováno v:
Molecules, Vol 26, Iss 19, p 6042 (2021)
We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug conjugates used clinically as cancer treatments. While providing both effica
Externí odkaz:
https://doaj.org/article/9008e7e4c9de44cb83d43651ec422808